Abstracts tagged "biologic response modifiers"

Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Jean-Pascal Roussy¹, Louis Bessette², Sasha Bernatsky³, Elham Rahme⁴ and Jean Lachaine¹, ¹Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…
Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Diane Lacaille¹, Michal Abrahamowicz², Eric C. Sayre³ and John Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Cesar Vargas-Serafin¹, Luis Aguilar-Lozano¹, Jorge Padilla-Ibarra¹, Carlos Sandoval-Castro¹, Jose Dionisio Castillo-Ortiz¹, Jorge Morales-Torres², Claudia Hernandez² and Cesar Ramos-Remus¹, ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Rheumatology, Hospital Aranda de la Parra, Leon, Mexico
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…
Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting
Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Chi Chiu Mok¹, Cherry Kwan¹, Helen Chan², Ka Lai Lee³ and Lai-Shan Tam⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rehabilitation, Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, ³Medicine, Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…
Abstract Number: 1569 • 2012 ACR/ARHP Annual Meeting
Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-2
Mie Fusama¹, Hideko Nakahara², Keisuke Kawamoto³, Satoko Nozato³, Midori Taguchi³, Kohji Nishioka³, Shinji Higa³, Eiji Takeuchi⁴, Kayoko Higashi⁵, Masao Yukioka⁶, Tsuyoshi Igarashi³, Taro Kuritani³, Keiji Maeda³ and Yasushi Miura⁷, ¹Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ³Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, NTT West Osaka Hospital, Osaka, Japan, ⁵Division of nursing, NTT West Osaka Hospital, Osaka, Japan, ⁶Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
Background/Purpose: Biologics significantly improve disease activity of rheumatoid arthritis (RA), however, patient global assessment (PGA) is not always improved in parallel with disease activity scores.…
Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Paul Emery¹, Piotr Wiland², Wolfgang Spieler³, Jean Dudler⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁵, Andrew S. Koenig⁵, Bonnie Vlahos⁵ and Sameer Kotak⁶, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
Abstract Number: 1552 • 2012 ACR/ARHP Annual Meeting
Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the ‘Biologic Era’ : A Case-Control Study
Ashima Makol¹, Cynthia S. Crowson², Eric L. Matteson³ and Kenneth J. Warrington¹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: 1.To determine the clinical presentation, treatment and outcomes of vasculitis (RV) associated with rheumatoid arthritis (RA) in the era of biologic use. 2. To…
Abstract Number: 1163 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Tomohiro Kubota¹, Tsuyoshi Yamatou², Yukiko Nonaka², Harumi Akaike², Tomokazu Nagakura³, Yuichi Yamasaki¹, Tomoko Takezaki², Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁴School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Progression of joint damage is sometimes observed in JIA patients during the biologic therapy. However, it is difficult to evaluate the radiographic progression by…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].